Henry Meds' reviewed injectable semaglutide program concerns compounded medication. The first clinical-literacy question is why that preparation is being proposed for the individual, not simply whether its ingredient appears in an approved drug.
Preserve the approval distinction
FDA does not approve compounded products. Its GLP-1 guidance advises considering them when an available approved medicine cannot meet the patient's medical needs. Ask the prescriber to explain that reasoning and identify the product and dispensing pharmacy.
Our terminology briefing distinguishes compounding from an off-label use of an approved medicine. The concepts should not be used interchangeably in a service comparison.
Read the bundle at its stated scope
The published monthly injectable semaglutide terms list $297. Henry describes visits, medication, supplies, shipping and ongoing care within the program. Other purchase periods and formulations have different terms; the monthly figure is not a universal quote for the whole menu.
The company also notes that cancelling a multi-month plan may leave a balance payable, subject to its stated medical exception. Obtain the actual agreement before relying on a general cancellation headline.
Know who explains the dispensed product
A dosing or packaging question should reach the professional who can inspect the actual prescription. The pharmacy-role guide explains why a support desk and a dispensing pharmacist are not interchangeable contacts. We have not purchased Henry treatment or inspected its pharmacies. The profile establishes a public offer and questions for assessment, without certifying the preparation or forecasting an individual result.
Source notes
Checked October 5, 2026. Provider pages document advertised terms. Study summaries identify the scope of our review.
- Henry | Personalized Weight Loss, Hormone & Sexual Health CareProvider public offer; checked October 5, 2026
- Henry | Personalized Weight Loss, Hormone & Sexual Health CareProvider public offer; checked October 5, 2026
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight LossPrimary health resource; checked October 5, 2026